Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Interferons in the Treatment of Multiple Sclerosis

Interferons in the Treatment of Multiple Sclerosis CONTROVERSIES IN NEUROLOGY SECTION EDITOR: VLADIMIR HACHINSKI, MD, FRCPC, DSCMED Do They Prevent the Progression of the Disease? George Rice, MD, FRCPC; George Ebers, MD, FRCPC HERE IS little doubt score on the Kurtzke Expanded Dis- duction by presenting the attack fre- that treatment of ability Status Scale) compared with quency in patients followed up for multiple sclerosis 28% of patients treated with pla- 102 weeks. This percentage de- (MS) with type 1 in- cebo. This difference did not reach rived from a post hoc subgroup T terferons reduces the statistical significance (P = .16). analysis that was not corrected for frequency of clinical exacerba- Several reasons were offered to the statistically challenging effect of tions. This observation has been cor- explain this shortfall in disability multiple comparison. Further- roborated repeatedly. Treatment of outcome. First, the study was nei- more, much of the effect can be at- 124 patients with recombinant in- ther designed nor powered statisti- tributed to an unusually high fre- terferon beta-1b (IFN-b-1b) re- cally to identify a moderate effect on quency of attacks that occurred in duced the frequency of attacks by disease progression. This would have small numbers of patients in the pla- 33.8%. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Neurology American Medical Association

Interferons in the Treatment of Multiple Sclerosis

JAMA Neurology , Volume 55 (12) – Dec 1, 1998

Loading next page...
 
/lp/american-medical-association/interferons-in-the-treatment-of-multiple-sclerosis-sDws0kYqa6
Publisher
American Medical Association
Copyright
Copyright 1998 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6149
eISSN
2168-6157
DOI
10.1001/archneur.55.12.1578
Publisher site
See Article on Publisher Site

Abstract

CONTROVERSIES IN NEUROLOGY SECTION EDITOR: VLADIMIR HACHINSKI, MD, FRCPC, DSCMED Do They Prevent the Progression of the Disease? George Rice, MD, FRCPC; George Ebers, MD, FRCPC HERE IS little doubt score on the Kurtzke Expanded Dis- duction by presenting the attack fre- that treatment of ability Status Scale) compared with quency in patients followed up for multiple sclerosis 28% of patients treated with pla- 102 weeks. This percentage de- (MS) with type 1 in- cebo. This difference did not reach rived from a post hoc subgroup T terferons reduces the statistical significance (P = .16). analysis that was not corrected for frequency of clinical exacerba- Several reasons were offered to the statistically challenging effect of tions. This observation has been cor- explain this shortfall in disability multiple comparison. Further- roborated repeatedly. Treatment of outcome. First, the study was nei- more, much of the effect can be at- 124 patients with recombinant in- ther designed nor powered statisti- tributed to an unusually high fre- terferon beta-1b (IFN-b-1b) re- cally to identify a moderate effect on quency of attacks that occurred in duced the frequency of attacks by disease progression. This would have small numbers of patients in the pla- 33.8%.

Journal

JAMA NeurologyAmerican Medical Association

Published: Dec 1, 1998

References